Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cingulate Inc.CING · Entity 6983 | EVP and Chief Medical Officer | July 16, 2026 | July 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cingulate Inc.
Report date July 16, 2026 · Filed July 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.43 · Expires 2036-07-16 | Direct | 53,600 |
Reported balance
After 2026-07-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-16 · Grant · Acquired 53,600 · Balance 53,600 F1: The option vests as follows: 25% on March 31, 2027 and the remaining shares in substantially equal monthly installments over the 36-month period following the initial vesting date. |
| Stock Option (right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.43 · Expires 2036-07-16 | Direct | 26,400 |
Reported balance
After 2026-07-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-07-16 · Grant · Acquired 26,400 · Balance 26,400 F1: The option vests as follows: 25% on March 31, 2027 and the remaining shares in substantially equal monthly installments over the 36-month period following the initial vesting date. F2: Vested option only becomes exercisable if the Issuer's NDA for CTx-1301 is approved by the FDA during 2027. F3: If the Issuer's NDA for CTx-1301 is not approved by the FDA during 2027, the option, including any vested portion, shall terminate. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests as follows: 25% on March 31, 2027 and the remaining shares in substantially equal monthly installments over the 36-month period following the initial vesting date.
F2: Vested option only becomes exercisable if the Issuer's NDA for CTx-1301 is approved by the FDA during 2027.
F3: If the Issuer's NDA for CTx-1301 is not approved by the FDA during 2027, the option, including any vested portion, shall terminate.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 16, 2026 Filed Jul 20, 2026 23:32 UTC | Cingulate Inc. CING · Entity 6983 | GrantStock Option (right to Buy) · Derivative | 26,400 | $0.00 Strike: $4.43 | $0.00 |
DisclosureSEC source: 0001493152-26-033967 · ownership.xml · derivative · entry 2 Brams Matthew · CIK 0001884361 · EVP and Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,400 Underlying: Common Stock · 26,400 shares Expires 2036-07-16 F1 · derivative.exercise_date: The option vests as follows: 25% on March 31, 2027 and the remaining shares in substantially equal monthly installments over the 36-month period following the initial vesting date. F2 · derivative.exercise_date: Vested option only becomes exercisable if the Issuer's NDA for CTx-1301 is approved by the FDA during 2027. F3 · derivative.expiration_date: If the Issuer's NDA for CTx-1301 is not approved by the FDA during 2027, the option, including any vested portion, shall terminate. Read SEC document |
| July 16, 2026 Filed Jul 20, 2026 23:32 UTC | Cingulate Inc. CING · Entity 6983 | GrantStock Option (right to Buy) · Derivative | 53,600 | $0.00 Strike: $4.43 | $0.00 |
DisclosureSEC source: 0001493152-26-033967 · ownership.xml · derivative · entry 1 Brams Matthew · CIK 0001884361 · EVP and Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,600 Underlying: Common Stock · 53,600 shares Expires 2036-07-16 F1 · derivative.exercise_date: The option vests as follows: 25% on March 31, 2027 and the remaining shares in substantially equal monthly installments over the 36-month period following the initial vesting date. Read SEC document |
| March 09, 2026 Filed Mar 12, 2026 00:13 UTC | Cingulate Inc. CING · Entity 6983 | Tax withholdingCommon Stock | 1,025 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-26-009719 · ownership.xml · nonDerivative · entry 2 Brams Matthew · CIK 0001884361 · EVP and Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,157 F2 · security: Shares otherwise issuable were withheld to satisfy the Reporting Person's tax obligations on the grant described in footnote 1 above. Read SEC document |
| March 09, 2026 Filed Mar 12, 2026 00:13 UTC | Cingulate Inc. CING · Entity 6983 | GrantCommon Stock | 4,526 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-26-009719 · ownership.xml · nonDerivative · entry 1 Brams Matthew · CIK 0001884361 · EVP and Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,182 F1 · security: Shares of common stock were granted pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended, for a portion of the Reporting Person's 2025 bonus. Read SEC document |
| February 06, 2026 Filed Feb 11, 2026 00:00 UTC | Cingulate Inc. CING · Entity 6983 | PurchaseWarrant to Purchase Common Stock · Derivative | 1,556 | $0.10 Strike: $5.04 | $155.60 |
DisclosureSEC source: 0001493152-26-006024 · ownership.xml · derivative · entry 2 Brams Matthew · CIK 0001884361 · EVP and Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,556 Underlying: Common Stock · 1,556 shares Expires not disclosed F1 · date: Common stock and warrants were acquired in the Issuer's private placement disclosed in the Current Report on Form 8-K filed with the SEC on January 28, 2026. F2 · derivative.exercise_date: The warrant is exercisable upon the Issuer obtaining stockholder approval of the private placement, as required by the Nasdaq rules. The expiration date of the warrant is 36 months after the exercise date. F2 · derivative.expiration_date: The warrant is exercisable upon the Issuer obtaining stockholder approval of the private placement, as required by the Nasdaq rules. The expiration date of the warrant is 36 months after the exercise date. Read SEC document |
| February 06, 2026 Filed Feb 11, 2026 00:00 UTC | Cingulate Inc. CING · Entity 6983 | PurchaseCommon Stock | 1,946 | $5.04 | $9,807.84 |
DisclosureSEC source: 0001493152-26-006024 · ownership.xml · nonDerivative · entry 1 Brams Matthew · CIK 0001884361 · EVP and Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,656 F1 · date: Common stock and warrants were acquired in the Issuer's private placement disclosed in the Current Report on Form 8-K filed with the SEC on January 28, 2026. Read SEC document |
| July 07, 2025 Filed Jul 9, 2025 22:00 UTC | Cingulate Inc. CING · Entity 6983 | GrantStock Option (right to Buy) · Derivative | 52,500 | $0.00 Strike: $4.42 | $0.00 |
DisclosureSEC source: 0001641172-25-018476 · ownership.xml · derivative · entry 1 Brams Matthew · CIK 0001884361 · EVP and Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,500 Underlying: Common Stock · 52,500 shares Expires 2035-07-07 F1 · derivative.exercise_date: The option vests as follows: 25% on the one-year anniversary of the date of grant and the remaining shares in substantially equal monthly installments over the 36-month period following the initial vesting date. Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 23:00 UTC | Cingulate Inc. CING · Entity 6983 | GrantStock Option (right to Buy) · Derivative | 17,630 | $0.00 Strike: $4.32 | $0.00 |
DisclosureSEC source: 0001493152-25-007758 · ownership.xml · derivative · entry 1 Brams Matthew · CIK 0001884361 · EVP and Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,630 Underlying: Common Stock · 17,630 shares Expires 2035-02-18 F1 · derivative.exercise_date: The option vests as follows: 25% on the one-year anniversary of the date of grant and the remaining shares in substantially equal monthly installments over the 36-month period following the initial vesting date. Read SEC document |
| January 17, 2025 Filed Jan 23, 2025 00:00 UTC | Cingulate Inc. CING · Entity 6983 | GrantStock Option (right to Buy) · Derivative | 2,748 | $0.00 Strike: $4.76 | $0.00 |
DisclosureSEC source: 0001493152-25-003288 · ownership.xml · derivative · entry 1 Brams Matthew · CIK 0001884361 · EVP and Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,748 Underlying: Common Stock · 2,748 shares Expires 2035-01-17 F1 · date: The option was granted for a portion of Mr. Bram's 2024 bonus. Read SEC document |
| December 31, 2024 Filed Jan 8, 2025 01:30 UTC | Cingulate Inc. CING · Entity 6983 | GrantStock Option (right to Buy) · Derivative | 1,000 | $0.00 Strike: $4.93 | $0.00 |
DisclosureSEC source: 0001493152-25-001274 · ownership.xml · derivative · entry 1 Brams Matthew · CIK 0001884361 · EVP and Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,000 Underlying: Common Stock · 1,000 shares Expires 2034-12-31 F1 · date: The option was granted pursuant to the terms of Mr. Bram's Employment Agreement, as amended. Read SEC document |
| September 30, 2024 Filed Oct 1, 2024 22:00 UTC | Cingulate Inc. CING · Entity 6983 | GrantStock Option (right to Buy) · Derivative | 1,000 | $0.00 Strike: $5.04 | $0.00 |
DisclosureSEC source: 0001493152-24-039066 · ownership.xml · derivative · entry 1 Brams Matthew · CIK 0001884361 · EVP and Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,000 Underlying: Common Stock · 1,000 shares Expires 2034-09-30 F1 · date: The option was granted pursuant to the terms of Mr. Bram's Employment Agreement, as amended. Read SEC document |
| June 28, 2024 Filed Jul 3, 2024 00:00 UTC | Cingulate Inc. CING · Entity 6983 | GrantStock Option (right to Buy) · Derivative | 1,000 | $0.00 Strike: $0.32 | $0.00 |
DisclosureSEC source: 0001493152-24-026099 · ownership.xml · derivative · entry 1 Brams Matthew · CIK 0001884361 · EVP and Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,000 Underlying: Common Stock · 1,000 shares Expires 2034-06-28 F1 · date: The option was granted pursuant to the terms of Mr. Bram's Employment Agreement, as amended. Read SEC document |
| June 11, 2024 Filed Jun 13, 2024 23:59 UTC | Cingulate Inc. CING · Entity 6983 | GrantStock Option (right to Buy) · Derivative | 63,324 | $0.00 Strike: $1.18 | $0.00 |
DisclosureSEC source: 0001493152-24-023766 · ownership.xml · derivative · entry 1 Brams Matthew · CIK 0001884361 · EVP and Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,324 Underlying: Common Stock · 63,324 shares Expires 2034-03-04 F1 · date: The stock option grant was approved by Cingulate Inc.'s board of directors on March 4, 2024, subject to stockholder approval of Amendment No.1 to the Cingulate Inc. 2021 Omnibus Equity Incentive Plan (the "Amendment"). Cingulate's stockholders approved the Amendment on June 11, 2024. F2 · derivative.exercise_date: The option vests as follows: 50% on the six-month anniversary of the date of grant and the remaining shares in substantially equal monthly installments over the 30-month period following the initial vesting date. Read SEC document |
| March 29, 2024 Filed Apr 1, 2024 23:00 UTC | Cingulate Inc. CING · Entity 6983 | GrantStock Option (right to Buy) · Derivative | 1,000 | $0.00 Strike: $1.10 | $0.00 |
DisclosureSEC source: 0001493152-24-012568 · ownership.xml · derivative · entry 1 Brams Matthew · CIK 0001884361 · EVP and Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,000 Underlying: Common Stock · 1,000 shares Expires 2034-03-29 F1 · date: The option was granted pursuant to the terms of Mr. Bram's Employment Agreement, as amended. Read SEC document |
| March 04, 2024 Filed Mar 6, 2024 23:00 UTC | Cingulate Inc. CING · Entity 6983 | GrantStock Option (right to Buy) · Derivative | 16,676 | $0.00 Strike: $1.18 | $0.00 |
DisclosureSEC source: 0001493152-24-009090 · ownership.xml · derivative · entry 1 Brams Matthew · CIK 0001884361 · EVP and Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,676 Underlying: Common Stock · 16,676 shares Expires 2034-03-04 F1 · derivative.exercise_date: The option vests as follows: 50% on the six-month anniversary of the date of grant and the remaining shares in substantially equal monthly installments over the 30-month period following the initial vesting date. Read SEC document |
| February 28, 2023 Filed Mar 9, 2023 02:01 UTC | Cingulate Inc. CING · Entity 6983 | GrantStock Option (right to Buy) · Derivative | 15,000 | $0.00 Strike: $1.79 | $0.00 |
DisclosureSEC source: 0001493152-23-007040 · ownership.xml · derivative · entry 1 Brams Matthew · CIK 0001884361 · EVP and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2033-02-28 F1 · derivative.exercise_date: The option vests as follows: 25% on the one-year anniversary of the date of grant and the remaining shares in substantially equal monthly installments over the 36-month period following the initial vesting date. Read SEC document |
| February 25, 2022 Filed Mar 1, 2022 23:00 UTC | Cingulate Inc. CING · Entity 6983 | GrantStock Option (right to Buy) · Derivative | 12,500 | $0.00 Strike: $1.38 | $0.00 |
DisclosureSEC source: 0001493152-22-005780 · ownership.xml · derivative · entry 1 Brams Matthew · CIK 0001884361 · EVP and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2032-02-25 F1 · derivative.exercise_date: The option vests as follows: 25% on the one-year anniversary of the date of grant and the remaining shares in substantially equal monthly installments over the 36-month period following the initial vesting date. Read SEC document |
| December 07, 2021 Filed Dec 9, 2021 23:00 UTC | Cingulate Inc. CING · Entity 6983 | GrantStock Option (right to Buy) · Derivative | 4,492 | $0.00 Strike: $6.00 | $0.00 |
DisclosureSEC source: 0001493152-21-031006 · ownership.xml · derivative · entry 1 Brams Matthew · CIK 0001884361 · EVP and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,492 Underlying: Common Stock · 4,492 shares Expires 2031-12-07 F1 · derivative.exercise_date: The option vests in four equal annual installments commencing on December 7, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.